Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

4-Hydroxynonenal Promotes Growth and Angiogenesis of Breast Cancer Cells through HIF-1α Stabilization

  • Li, Yao-Ping (Shanxi Breast Cancer Center, Shanxi Cancer Center) ;
  • Tian, Fu-Guo (Breast Cancer Department, Shanxi Cancer Center) ;
  • Shi, Peng-Cheng (Breast Cancer Department, Shanxi Cancer Center) ;
  • Guo, Ling-Yun (Breast Cancer Department, Shanxi Cancer Center) ;
  • Wu, Hai-Ming (Breast Cancer Department, Shanxi Cancer Center) ;
  • Chen, Run-Qi (Breast Cancer Department, Shanxi Cancer Center) ;
  • Xue, Jin-Ming (Breast Cancer Department, Shanxi Cancer Center)
  • Published : 2015.01.06
Download PDF
⟨ Previous Next ⟩

Abstract

4-Hydroxynonenal (4-HNE) is a stable end product of lipid peroxidation, which has been shown to play an important role in cell signal transduction, while increasing cell growth and differentiation. 4-HNE could inhibit phosphatase and tensin homolog (PTEN) activity in hepatocytes and increased levels have been found in human invasive breast cancer. Here we report that 4-HNE increased the cell growth of breast cancer cells as revealed by colony formation assay. Moreover, vascular endothelial growth factor (VEGF) expression was elevated, while protein levels of hypoxia inducible factor 1 alpha (HIF-$1{\alpha}$) were up-regulated. Sirtuin-3 (SIRT3), a major mitochondria NAD+-dependent deacetylase, is reported to destabilize HIF-$1{\alpha}$. Here, 4-HNE could inhibit the deacetylase activity of SIRT3 by thiol-specific modification. We further demonstrated that the regulation by 4-HNE of levels of HIF-$1{\alpha}$ and VEGF depends on SIRT3. Consistent with this, 4-HNE could not increase the cell growth in SIRT3 knockdown breast cancer cells. Additionally, 4-HNE promoted angiogenesis and invasion of breast cancer cells in a SIRT3-dependent manner. In conclusion, we propose that 4-HNE promotes growth, invasion and angiogenesis of breast cancer cells through the SIRT3-HIF-$1{\alpha}$-VEGF axis.

Keywords

References

  1. Ahn GO, Seita J, Hong BJ, et al (2014). Transcriptional activation of hypoxia-inducible factor-1 (HIF-1) in myeloid cells promotes angiogenesis through VEGF and S100A8. Proc Natl Acad Sci U S A, 111, 2698-703. https://doi.org/10.1073/pnas.1320243111
  2. Ayala A, Munoz MF, Arguelles S (2014). Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev, 2014, 360438.
  3. Bennaars-Eiden A, Higgins L, Hertzel AV, et al (2002). Covalent modification of epithelial fatty acid-binding protein by 4-hydroxynonenal in vitro and in vivo. Evidence for a role in antioxidant biology. J Biol Chem, 277, 50693-702. https://doi.org/10.1074/jbc.M209493200
  4. Caito S, Rajendrasozhan S, Cook S, et al (2010). SIRT1 is a redox-sensitive deacetylase that is post-translationally modified by oxidants and carbonyl stress. FASEB J, 24, 3145-59. https://doi.org/10.1096/fj.09-151308
  5. Cao ZG, Xu X, Xue YM,Zhao SL (2014). Comparison of 4-hydroxynonenal-induced p53-mediated apoptosis in prostate cancer cells LNCaP and DU145. Contemp Oncol (Pozn), 18, 22-8.
  6. Chen Y, Fu LL, Wen X, et al (2014). Sirtuin-3 (SIRT3), a therapeutic target with oncogenic and tumor-suppressive function in cancer. Cell Death Dis, 5, 1047. https://doi.org/10.1038/cddis.2014.14
  7. Christov PP, Hawkins EK, Kett NR, et al (2013). Simplified synthesis of individual stereoisomers of the 4-hydroxynonenal adducts of deoxyguanosine. Tetrahedron Lett, 54, 4289-91. https://doi.org/10.1016/j.tetlet.2013.06.004
  8. Dalleau S, Baradat M, Gueraud F, et al (2013). Cell death and diseases related to oxidative stress: 4-hydroxynonenal (HNE) in the balance. Cell Death Differ, 20, 1615-30. https://doi.org/10.1038/cdd.2013.138
  9. Finley LW, Carracedo A, Lee J, et al (2011). SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell, 19, 416-28. https://doi.org/10.1016/j.ccr.2011.02.014
  10. Fritz KS, Galligan JJ, Smathers RL, et al (2011). 4-Hydroxynonenal inhibits SIRT3 via thiol-specific modification. Chem Res Toxicol, 24, 651-62. https://doi.org/10.1021/tx100355a
  11. Groulx I, Lee S (2002). Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclearcytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. Mol Cell Biol, 22, 5319-36. https://doi.org/10.1128/MCB.22.15.5319-5336.2002
  12. Jin H, Zangar RC (2009). Protein modifications as potential biomarkers in breast cancer. Biomark Insights, 4, 191-200.
  13. Ke Q, Costa M (2006). Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol, 70, 1469-80. https://doi.org/10.1124/mol.106.027029
  14. Kim JW, Tchernyshyov I, Semenza GL, et al (2006). HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab, 3, 177-85. https://doi.org/10.1016/j.cmet.2006.02.002
  15. Lee S, Chen TT, Barber CL, et al (2007). Autocrine VEGF signaling is required for vascular homeostasis. Cell, 130, 691-703. https://doi.org/10.1016/j.cell.2007.06.054
  16. Li DW, Dong P, Wang F, et al (2013). Hypoxia induced multidrug resistance of laryngeal cancer cells via hypoxia-inducible factor-1 alpha. Asian Pac J Cancer Prev, 14, 4853-8. https://doi.org/10.7314/APJCP.2013.14.8.4853
  17. Lopez-Lazaro M (2006). HIF-1: hypoxia-inducible factor or dysoxia-inducible factor? FASEB J, 20, 828-32. https://doi.org/10.1096/fj.05-5168hyp
  18. Macpherson LJ, Xiao B, Kwan KY, et al (2007). An ion channel essential for sensing chemical damage. J Neurosci, 27, 11412-5. https://doi.org/10.1523/JNEUROSCI.3600-07.2007
  19. Maxwell PH, Wiesener MS, Chang GW, et al (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature, 399, 271-5. https://doi.org/10.1038/20459
  20. Park JH, Kim TY, Jong HS, et al (2003). Gastric epithelial reactive oxygen species prevent normoxic degradation of hypoxia-inducible factor-1alpha in gastric cancer cells. Clin Cancer Res, 9, 433-40.
  21. Patrick B, Li J, Jeyabal PV, et al (2005). Depletion of 4-hydroxynonenal in hGSTA4-transfected HLE B-3 cells results in profound changes in gene expression. Biochem Biophys Res Commun, 334, 425-32. https://doi.org/10.1016/j.bbrc.2005.06.099
  22. Pugh CW, Ratcliffe PJ (2003). Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med, 9, 677-84. https://doi.org/10.1038/nm0603-677
  23. Ryan BJ, Nissim A, Winyard PG (2014). Oxidative posttranslational modifications and their involvement in the pathogenesis of autoimmune diseases. Redox Biol, 2, 715-24. https://doi.org/10.1016/j.redox.2014.05.004
  24. Sharma R, Sharma A, Dwivedi S, et al (2008). 4-Hydroxynonenal self-limits fas-mediated DISC-independent apoptosis by promoting export of Daxx from the nucleus to the cytosol and its binding to Fas. Biochemistry, 47, 143-56. https://doi.org/10.1021/bi701559f
  25. Sharma R, Sharma A, Chaudhary P, et al (2012). Role of 4-hydroxynonenal in chemopreventive activities of sulforaphane. Free Radic Biol Med, 52, 2177-85. https://doi.org/10.1016/j.freeradbiomed.2012.04.012
  26. Shearn CT, Fritz KS, Reigan P, et al (2011a). Modification of Akt2 by 4-hydroxynonenal inhibits insulin-dependent Akt signaling in HepG2 cells. Biochemistry, 50, 3984-96. https://doi.org/10.1021/bi200029w
  27. Shearn CT, Smathers RL, Stewart BJ, et al (2011b). Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) inhibition by 4-hydroxynonenal leads to increased Akt activation in hepatocytes. Mol Pharmacol, 79, 941-52. https://doi.org/10.1124/mol.110.069534
  28. Sovic A, Borovic S, Loncaric I, et al (2001). The carcinostatic and proapoptotic potential of 4-hydroxynonenal in HeLa cells is associated with its conjugation to cellular proteins. Anticancer Res, 21, 1997-2004.
  29. Stroka DM, Burkhardt T, Desbaillets I, et al (2001). HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J, 15, 2445-53.
  30. Szakacs G, Paterson JK, Ludwig JA, et al (2006). Targeting multidrug resistance in cancer. Nat Rev Drug Discov, 5, 219-34. https://doi.org/10.1038/nrd1984
  31. Ulrich HD (2007). SUMO teams up with ubiquitin to manage hypoxia. Cell, 131, 446-7. https://doi.org/10.1016/j.cell.2007.10.026
  32. Usatyuk PV, Natarajan V (2012). Hydroxyalkenals and oxidized phospholipids modulation of endothelial cytoskeleton, focal adhesion and adherens junction proteins in regulating endothelial barrier function. Microvasc Res, 83, 45-55. https://doi.org/10.1016/j.mvr.2011.04.012
  33. van Hagen M, Overmeer RM, Abolvardi SS, et al (2010). RNF4 and VHL regulate the proteasomal degradation of SUMOconjugated Hypoxia-Inducible Factor-2alpha. Nucleic Acids Res, 38, 1922-31. https://doi.org/10.1093/nar/gkp1157
  34. Vatsyayan R, Lelsani PC, Chaudhary P, et al (2012). The expression and function of vascular endothelial growth factor in retinal pigment epithelial (RPE) cells is regulated by 4-hydroxynonenal (HNE) and glutathione S-transferaseA4-4. Biochem Biophys Res Commun, 417, 346-51. https://doi.org/10.1016/j.bbrc.2011.11.113
  35. Xu N, Lei Z, Li XL, et al (2013). Clinical study of tumor angiogenesis and perfusion imaging using multi-slice spiral computed tomography for breast cancer. Asian Pac J Cancer Prev, 14, 429-33. https://doi.org/10.7314/APJCP.2013.14.1.429
  36. Zhu K, Jiao H, Li S, et al (2013). ATF4 promotes bone angiogenesis by increasing VEGF expression and release in the bone environment. J Bone Miner Res, 28, 1870-8 https://doi.org/10.1002/jbmr.1958

Cited by

  1. Mitochondrial Dysfunction in Cancer and Neurodegenerative Diseases: Spotlight on Fatty Acid Oxidation and Lipoperoxidation Products vol.5, pp.1, 2016, https://doi.org/10.3390/antiox5010007
  2. Voltage-gated calcium channels: Novel targets for cancer therapy vol.14, pp.2, 2017, https://doi.org/10.3892/ol.2017.6457